<SEC-DOCUMENT>0001144204-14-055797.txt : 20140915
<SEC-HEADER>0001144204-14-055797.hdr.sgml : 20140915
<ACCEPTANCE-DATETIME>20140915071758
ACCESSION NUMBER:		0001144204-14-055797
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140912
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140915
DATE AS OF CHANGE:		20140915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		141102124

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v389096_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):
September 12, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><U>STAAR Surgical
Company</U></FONT><BR>
<FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Delaware</U><BR>
        (State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="width: 33%; text-decoration: none; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>0-11634</U></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>95-3797439</U><BR>
        (I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1911 Walker Ave, Monrovia, California<BR>
 (Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-decoration: none; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>91016</U></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
Applicable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Former name or former address, if changed since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.02</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective September 12, 2014, the Board
of Directors of STAAR Surgical Company elected Louis Silverman, 56, to serve in a newly created seat pursuant to an increase in
size of the Board from seven to eight members. Mr. Silverman will serve as chairman of the Compensation Committee and as a member
of the Nominating and Governance committee. The Board approved providing Mr. Silverman with the standard director compensation
for a director, pro-rated for the remaining portion of the 2014-2015 term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Silverman is currently the Chairman
and CEO of privately held Advanced ICU Care, Inc. a rapidly growing technology enabled health care services company providing tele-ICU
monitoring services to hospitals nationwide and he also advised boards of directors on growth and general corporate strategy initiatives.
From June 2012 through February 2014, Mr. Silverman served as a consultant and Board advisor for private equity investors regarding
health care technology and health care services portfolio investments. From September 2009 through June 2012, Mr. Silverman was
CEO of Marina Medical, Inc. where he achieved a successful exit for the privately held Company. Previously, Mr. Silverman served
as President and CEO of Qualcomm-backed health care<FONT STYLE="color: red"> </FONT>start-up LifeComm, and he has also served as
COO of Corvel Corporation, a publicly traded national managed care services/technology company that generated seven consecutive
years of revenue and earnings growth during his tenure. For eight years, from August 2000 through August 2008, Mr. Silverman also
served as the President and CEO of Quality Systems, Inc., a publicly traded developer of medical and dental practice management
and patient records<FONT STYLE="color: red"> </FONT>software. During his tenure, the Company&rsquo;s revenue increased from an
annualized run rate of approximately $35 million to<FONT STYLE="color: red"> </FONT>an annualized revenue run rate of $250 million
and an<FONT STYLE="color: red"> </FONT>increase in the Company&rsquo;s market capitalization from approximately $45 million to
approximately $1.2 billion. The Company was named to the Forbes 200 list of Best Small Companies during<FONT STYLE="color: red">
</FONT>each year of his tenure. Mr.&nbsp;Silverman earned a B.A. from Amherst College and an M.B.A. from Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The appointment of Mr. Silverman to the
Board was not the result of any arrangement or understanding between him and any other person or entity. There are no transactions
between Mr. Silverman nor any member of his immediate family and the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 7.01</B></TD><TD STYLE="text-align: justify"><B>Regulation FD Disclosure</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 15, 2014, the Company published
a press release regarding the election of Mr. Silverman to the Board, and an increase in the size of the Board from seven to eight
members. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information furnished herewith pursuant
to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless
of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press release of the Company dated September 15, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September 15, 2014</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Barry G. Caldwell</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Barry G. Caldwell</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v389096_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: center"><IMG SRC="tlogo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOUIS SILVERMAN APPOINTED TO STAAR SURGICAL
BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Appointment of Healthcare Industry Leader
Expands STAAR&rsquo;s Board to Eight</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MONROVIA, CA, September 15, 2014</B> &mdash; STAAR Surgical
Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today
announced that its Board of Directors has appointed<FONT STYLE="color: red"> </FONT>Louis E. Silverman, to the Company&rsquo;s
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Silverman is currently the Chairman and CEO of privately
held Advanced ICU Care, Inc. a rapidly growing technology enabled health care services company providing tele-ICU monitoring services
to hospitals nationwide. Previously, Mr. Silverman was CEO of Marina Medical, Inc. where he achieved a successful exit for the
privately held Company, and President and CEO of Qualcomm-backed health care<FONT STYLE="color: red"> </FONT>start-up LifeComm.
Mr. Silverman has also served as COO of Corvel Corporation, a publicly traded national managed care services/technology company
that generated seven consecutive years of revenue and earnings growth during his tenure, and he has advised private equity investors
on healthcare technology and services portfolio investments as well as boards of directors on growth and general corporate strategy
initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For eight years, Mr. Silverman also served as the President
and CEO of Quality Systems, Inc., a publicly traded developer of medical and dental practice management and patient records<FONT STYLE="color: red">
</FONT>software. During his tenure, the Company&rsquo;s revenue increased from an annualized run rate of approximately $35 million
to<FONT STYLE="color: red"> </FONT>an annualized revenue run rate of $250 million and an<FONT STYLE="color: red"> </FONT>increase
in the Company&rsquo;s market capitalization from approximately $45 million to approximately $1.2 billion. The Company was named
to the Forbes 200 list of Best Small Companies during<FONT STYLE="color: red"> </FONT>each year of his tenure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Lou Silverman has a tremendous track record in developing
strategies that generate shareholder value,&rdquo; said Mark Logan, Chairman of the Board of STAAR Surgical. &ldquo;In addition
to his proven leadership as the CEO of several growth companies in the healthcare industry, Lou has been an active participant
on the Board of Directors of several high growth companies including Questcor Pharmaceuticals, which was recently acquired by Mallinkrodt
plc for $5.8 billion. We believe Lou&rsquo;s executive leadership experience with high growth healthcare companies will provide
valuable perspective to our Board and we look forward to his contributions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;STAAR Surgical is at an inflection point in the Company&rsquo;s
development as it continues to gain refractive procedure market share,&rdquo; said Mr. Silverman. &ldquo;I look forward to working
with the Board of Directors and the management to capitalize on the Company&rsquo;s growth opportunities while continuing to build
returns for shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All
of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR&rsquo;s lens used in refractive
surgery as an alternative to LASIK is called an Implantable Collamer&reg; Lens or &ldquo;ICL.&rdquo; A lens used to replace the
natural lens after cataract surgery is called an intraocular lens or &ldquo;IOL.&rdquo; More than 450,000 Visian ICLs have been
implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 335 full time employees and
markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in Aliso Viejo, CA and Monrovia, CA. For more
information, please visit the Company&rsquo;s website at <U>www.staar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">CONTACT:</TD>
    <TD STYLE="width: 20%"><B>Investors</B></TD>
    <TD STYLE="width: 60%"><B>Media</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>EVC Group</TD>
    <TD>EVC Group</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Doug Sherk</TD>
    <TD>Nicole Kruse</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>415-652-9100</TD>
    <TD>212-850-6025</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```(Z0``%M(``!_5```L'__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`3`#0`P$1
M``(1`0,1`?_$`0D``0`"`P$!`0$````````````%!@<("00"`0,!`0`#`0$!
M```````````````"`P0%`080``$$`0,#`P,"!@,!``````(!`P0%`!$2!A`@
M!R$3%$`Q(C`C)#1$%18(4$47.!$``@(`!`(&!`@)!PT``````@,!!``1$@4A
M$S%!42(4!F$R(Q40('&!D4)B@D"A4G*B4W,D!]$S0V.S9'8PL<&2LH.3HS1$
M=,46$@`!`P$%!04&!@,````````!`!$"(1`Q01(#(%%A(A,P\($R(W'!T5(S
M!$!0D:%"<N%B@A,!``$#`P(&`P$!`0```````1$`(3%!46%Q@1`@\)&AP4"Q
MT>$P\?_:``P#`0`"$0,1```![KU3J=-EQNJL%L0*Q3.SW0`_AXH&:[[]\ONB
MK^WH`````"GT6:N\G=/V0K-5DI*,%"5QNKJ--EINA3Z+,_\`2R9FW9OT````
M```\L?=*.#TLJ[*+KHJK=5GCC[D+33J+Q>AMSVN?D;53"61KE\/KQ'3\_/63
M<-U9OA9Z)BLW0L%4L=[*I"'LQ7*Q4S`_#GY\WULM[,^U/8PU6F?,_P"5[?3'
MZKB6FZ`Y]?7<K,_-T9MY>G0OZOE[[?*=27KES&^XXW4SX3M56^'/3[#E=.OA
M^SS,^VXUAIGO7\KT[/3,"'KEBW)?H+\YUNH7UO#YT_,=C9_K8<Q[LUTOK^O6
M.=E.M7;QYOY>G4;Z'!TE^+[%!UU8YV4XPW4['\;7IS]'S]Q?G.AHU]3S<IX+
M]CN-KR3BN``UNY>SU^M;^7LZ+?3\<`4#75*URM5$\:[:;SELC)^35<L<[*;I
MFM^7E8OAY_5WRV0%T;KFL``\WGNH/$Z%GNAM!UL(`IU%DM.,=&7K]\\7GOK]
M\_CX_26G&L566FZN*A(2\X^Z7@``U,XW0V,Z>*SW0`&,<E]^TTU:FR5G&O53
ME)Q^P6*V%6IG:+H47/;.61DYQF)Q``&(L6C+NW.```````````!$0E+SB```
M`````!__V@`(`0$``04"EI8,XURAA,@VM;9CUGS!BR.KCC;0'RFH58=A86F`
M.T?U;2EB6F7<=BN?;J>6M1W_`"!S*B6/YDISRWYS!O9#WF#C@87EV7-./_ZG
M>Y+9H8TZLXT^XGT#S+4AJ]XO=<*?XIY#JN2)9<(XM:Y7>.J*K8K_`!?Q*%D^
M?Q[B$!SD/*?(T[CG%ZOC$3)-C$B.2>34L%;CD]!0.V',N,U.67,N,TV??&KF
ML>MNE5<UEVPX8M@G+^-K:-<EHG;"9:P(#O9Y(X*%?GCRYOS@9;SG(<5FHY/S
M/E%/30**!TM.<R/'?/AYAXX\A09-'`EW/^P?\S>TE?R*JE26JZ%R\)WC?R*!
MBX%P\Y['CQP_'7DW#>:8_P!D_,,)[F\URJB2DZR9#S:2>+3+E[G-+*XYR.IG
M#9U?E2>=ARJK\?\`L5D,[F*B+JF4UW6<F:\E^,>"RN-^.`N&^#?[!_S.6#26
M<_GO!XW*^*^#>5.7W$FHPVL_SAQ5YNHXGR&-ROCH_P#TMYZA*7!>'63MQQ3M
M\H4B6G'/%\SY7$.(0/\`)?('8'%J!F45-7N'EIP_C=V345EEMBI@1GGF0?"%
MPOC%;,AUT.O&?60K1FKXGQ^DC?X=QK^ZO08DF'3\>J*!CM>:"0SX_P!]+7^)
MZSXG&^Q)54;[[<*,R#M8Z$O^WP8T9^JEO2UK8+3)0'W9AUL`/BQ<;FU#R?$C
M9'*KEG-6NKXK3;*)W7C95L^E@C65'85+(6TE,)*BU\"8PS;PW+"KJJ=ZLF7%
M8=B#,2;_`'.X@/6#,AD9#%3#GU\*0CZL1J1V!9WD!VTJ&$FH?=R&`DF9]3(]
MGW?H_P#_V@`(`0(``04"7=GNI@F)=A+HO9[H8A$7ZY`A8:(*['M%DOMXDX,.
M0+BK-:SYJKB?+<Q4;0A:7Z'[XXT;"LR0=PF&CP8S8H,1D<(FV1]QV2330-)B
M`18C#A8VPZZ@1WG,",\YT5LT;Z&V;2Y\=[8K+J`($7;*C[<C&YMPRT38Z^Z`
M"V/0(J3(GQYD0D=(6ZC[-.DR:(IE'VS8>-IZS/XR%FBK2UQ)&'>2=BKBM*:R
M`5IT"W#++<\,;04WIU<:-E84Z4+TSV_E5'VP?P&)*6._:,>U(5=@U;Z>Y(95
MA[_I:HOXJ0"-O]LL-S41=661]V3V>^ZH^X2=`D/-XJJN*X2HBZ84E\Q(R+!,
M@4WW7%^0]L0B0G'G'5[?OD;\!ACHUV:AJNB)^.+M%$4%Q=HXFU<7:.:)FX,T
M3$VKB[13T[W/Q(!VAV;%WJFJ"*HAIN$`45,=V(B[C%214U0$(1771`VDX.X$
MU[W!U7ZE?I/_V@`(`0,``04"33-F*BIV(G;L+%1$_70E3!]<W-Y[399\<L%I
M1SXYY\=$S]@<3=HI_1"8N8;)!B.FF*\2XK[BXB$XNP&4,U-<U1,WBF$8CBN`
MF*X`]-R:]$)"Z;PUWCJJHG:R[KCPCK@IJNX&P(E)>BN>T[[C3J;44I6$*$GV
M0]6G<+&OVGL_JWT]Q=.W>@XT2&!)HK":`KOJNU>HDAX\RWL:W>W*Z+ZJZWO"
M,>X/NLD/0"WC_624_;;7<':P6AOIHXXNQKLV#FU.B@!=-$Z(V"*B(F*B+B`(
MY[8:Z)H(B/>[^2OKJ?9^6>N>N)JN?DF)JN>N)JN:KFA9JN>J8FJKWCZH2ZEV
M;O1/155,%=%(M4%=,U305TZ$J*N;M4%="].\%]/^-__:``@!`@(&/P*BJN4[
M`XG9I54N[?\`V7KBGS#WK-HSS1XKU(*H*$H.T:JCIH1JL(A9:ZFJGU/TP_`L
M;EU-#R[DQI)5"(&*WIS0+)IT@FC8XN7(']B)TPX".2+LO3B]@U2/3)M:88L]
MG5;T]^"ZC<F].-GJPN7JW864;,FGYEEC=;`?;R'5B[CWKJ&)1TAY9&O@M;^G
MQ0U(>8)ABI_:#S0K'OWOLS&X*'WD?J1I+OWOLI\_O6IJ_<4TB&;>CEH#L4O3
MZA_2P2WK+N0J<ZYJVQ.^((4=-S*!-Q4^E]-UK?T^-F?$T^*CJ4RX^Q=2/TYU
M67$U/N1^VU/IZ@_=2TC@5_W[UTSY)`T4X"X2.T^(0X(S-P.SE)>*I2STY,Z=
M,;K!"4GB%S)XWK-J%Y+I9O3W+,*26;4+RVF4X_*5FQ.RR=#BG-R;%.4RK9PL
MI@G-W8:G&*$>&SFN3(`X(QWK@@UX*S&YE3>F67<J7IQ<R,0JW;??>/R[_]H`
M"`$#`@8_`JJBKL'9K1<>WX+TSX%-J18KD*O3'%8+F*WE/2$%R?Y_!9=2].+E
M>APM>59*MM5S*JK9EQMI9E_DFQVLDKUR7V5N3QN3FTYQRE,ZS8J'M64V#5P-
M]C(Z1\INL\$(P\RKL\HL9.KAE5+?%&5Q0S7J'ML994Q\P3KJ1\P69>"S8A`\
M-IM]@CCLOC;S;#@55%5,+EF_DFP7+MQ.]-N[!K*;;#L(<"GV6L/%/:UKV,4_
MYM__V@`(`0$!!C\"EM*1?'3-9L1J_P!TS4O.?04_/AD6ZEI7(X63KK.Y%7_R
MZZPC<*ORDG1V%.->WWJMR.OD/6PA]!A$ZPGT3$?$VE<SE-S<)K1Z?W&XW+_E
M?$EC3!8#Q(V%``,>DBRB,,&FT]S).?.G;QYU=,1TR^^1+V]$1]IL8@ZZ5U:D
M_P#<EF[7']1,BL'?+$2OL.<1$D1SUD66<_1$1_EA84MJW4Q/A=RI'R+U:?L-
M'UU3UK/4!=<8'_[3:H?7,]-;SIL('1MA,SW?>BJN1J=Z8U!/5&!O>4/.0;Y0
M.,U5]VY5G,?U8W-)]Z.R>7,8T^8?*H:!X391STJ+TP\?&5OQQB/$[3N*.WE'
M6LQ_MIG\6*%_:TW/#^69C>[T/4*CF/%TJ>D(%AP7[O8;UQTX]C3W9\_L4*CZ
M2LSCD;+Y9=9?/`1-YO+T>QJ(DOTL9M9M_E>J?]0++>G[*B*PR"^4@P%`W;K_
M`!%\S%/=INMD>VUS_+L@)340I<],%KRZ\L)L>8F5[!+R.KLE%<(V';<N(P%6
M,O&O7^L;GE]6(_`6(>L'):,@Q3!@UL`ND2$LXF)PW?O)CW>[\^9>VGO/!01Q
M(N3.?B*L?\1<=>70%*Y`;?NAQI\,THFM;G^Z-+UI+]67>^7!%9V>L+2_IJL3
M3;GVZJTKU3\N>-YKUSN&K>J?@6\]BV$A/?GV!<H>.LHGO9\1C$$RH[<#CZUZ
MP9CG^Q5R4_3$XYSHJ;;6Z%HK)6#+!Q'\VA"H@FG_`)NO![5L8GM&S#/[W8B9
MUPF>NW8#*9-D="5Y9]<Y<<>&V]6;3B/$W&1$V;1]K#^J&?0$=V/@6EK?WAHR
M2JRELL66`/`C&N@6-Y<3TEEIB<`.Y7(VLFE`)C<U.HP\RF!%=<[``M[2F?5"
M9+T8IHWC=*U!VXD844ND^;;->B#!"P$R842R.$=N*OO3=D[?XX^53\8NS7\2
MSN^S3#4C+#[\<([<*][;JK;8><+25U5JL#&3T`!M0($<]F>>,XZ\6]C5<4>[
M4:M>[;I1,\Y-6T1@AI<-.1ROMSCAVQ\+K.U7%74(N6J#6)F9$+=)LILIG.(X
MK./DF.,<,$P\](1G.0D<Y1V"$$1?-CW'&Z*G>>7SO=<*L>/Y6CF\SPO)YVCE
M\<\NC`[3&Y5U;H8<Q6WVM=.XX.C4BO;!+7Q'V(G"$VGPMMF<E!I(I*?NQ/\`
M+\5GF/9PA577![C4#N15891$7*W1I63)[PQZI<8]`K\R2I5,N6&TW-P>-?<+
MDE,"*82W([*^/=9.13T=[X&Q3*D>Z,4SW=4NVPJC:<.7=B2G466KJ^F.G!TM
MV*PJ\&;+Q6@D!V^G!Q$^'KSD.B9+)<#P*9SSZ\)V[;DPI"HXSTL<R?7<X^EC
M63TS_H^'S,_S9M6Y-\O;_P"ZRV??J:)LJJ)I4^45`XS$8"+!F<C$P4$4EE.K
M$[2K?]ML>(.NU5:P<4[J[5=P/K,0F\"C\0IP1,:8G&W;Y85#;FU5KM:AK@2&
MO-\J_/>&<9P^0KZ(GJ$I[<?PW_Q(S^TVW%O9]S5#JMM>F>$22F#.I-A,SZCD
M,B"&>V,-LNF>753JG\HY&,A`8ZV-/*!CKF<>6?X@/8TZ/F0?=_FGODQ:7L@8
M>H..4(KUN6:8_NTX%@%!@8P8&,YB0E&8D,QTQ,871KE(VMS;%-1#ZR5$,G<L
MQV37J"4Q/Y>F.O'F#^'ELSC:-^/WIY>8XI+-F@FI'F%ZS'51)1STDQ$=OP-8
MY@K"/+L1)'.4<=G7EQQY4V/REHM;_1W-FX-OJ8*1V:GRQ'GMM3(S&INDH$-1
M^SZ,5"O+&U9J@$0^=0%)P,:S[A1ZY1G\21JUBM/ZHDH2@?VKRB<H_-@R]&`?
MO^[L,%EK1MVV!%:E7*.@N8[G.L.C]9.DH^KIP7MK#U-D+^V6K#6/;I$\^63F
M212RLX<ODRGKQM^X#EE<IU['#J)JQ(Q^Z7#$459LC;:Z*B@'C,V;.3V0/VRY
M@#\V-LEN[[I7WFLJ&3:78APUGGWB4@'B>A*\],B)0)Y<<0G<Q3N`QPC<*(2D
MRCMLT"DM!=LJ(X^S&,XZ)^#=4#"&GM6[;ALVY4F:'<I]*P:QYJRCU+*8%@YQ
MEE/HQO>[^[*6Q[AM]"S>1N6WK"E^\5UDQ*G)3H0\;#8@,M.K,N[QQY9#?Y=.
M[1M:?$^)F9LC$R15PL27>YP59""SXYQQXX_AO_B1G]IMOP5]MF3\-3Y>Y796
MPU%+8.8VU',40G'M@)T_LA[<;KM$':.V29L;:5B];>"]QK1)U2T.>89&7<GA
MZISCW1?DHWGRJWW1<6W^>\,&J*+#B>.8`$IGTJQ9OL*P*:G,VVAR+%BMJT&,
M[B_-#%ZH9:7"X]"?3C;_`#MLI68WGRC;3:EQV+%EGN_G"<S$N8R8&I:TGE'U
M)/&T[_5RT;A5!C%Q_061]G;KSZ46`(?FPS_#G_IU8;N]:#5N6Q;CMUVG?KYK
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MIF8GN,8J>'&.^H@/\>+>X[?M":5[<)F;UNLRRE]N29S2E[`=$MF63GQZ\:*B
MR4$#H@.<]@".>?=%K#$>,]6#KWT^(0U3$-23&BIJ7#I8MJP,18)CPXYX\%M&
MW#MM3F$WPU-]I">8>6L^6M\#J++CCW[[J5[YY7)]Z<VSX[DZ.5R_$<[F:.7P
MRSZ,,V^S779I.3*'5K,>(6Y)1D2VP[7S(F.W/"ZNT5/!54\SD50?9.LB&EK9
M"$-<:TP1<<AB/C-0T=2G+-3!GH(&#(%$_*,X\[[:SUMDO6C^[%5NDOO#5B<3
MN!Q[?>+3+,E/3*%3*$_I"9?>^*:17##&UX-C!K&:AN:(;*#;`2`LTE'3PX]N
M&V&I7"D+-K)A6J8!8R1SI&)F<AC%%@)@@W&(*H7AB[XRF7Q)=SV42F,^]EA]
MRRI8(K+)SCA.O0L(U&>D!DI@1XX.NH`BPM*K!(97E3?#OU0IT"P!U*.0F,XZ
MXQS[0H4O6"XF5YD;&%`+4L!&38UA3E`C$S.)1%4EM%4.T.IFKV<E(1,$80!=
MZ.C/.,*.RH!%UA-5>FO+,WV#A:0R`2F-9SEV8SE"8C\P<)-2N8BPT4HLC3;-
M9K#+0.AW+TRLBZ#]2>W'\PK_`%!_DQ:77BNTZ3_#6A$(S2[0#-!9Q^2<>C#K
MMI2UUZX<QQPG7H".DM("13$8ABE"&L8^IH+*>.4]<?'_`(@RN,O>OE>I>7'Y
M3XBUMI_/):?IQMNWC&7A*59$_G`H8.?G//XJ]R4:*;O&2=M]0W#[QH0)BNK=
MIS'AVOB-/M?6'3PQ9K24C%A#D24<9&'+)<E'IC5C:J]DJVG:D"J#3+)FP2ZL
MTP+08CR8E99S&9<<;A020`RY3L5@-FK0$O62]10/>F!U8>WFJ>BTA$'S>8RY
M7<D=,I39/,F;=/K`LLN64SETXI$EHIL[=N"-QK2P9-)L2+%RIPQ,%H8MQ1G'
M$9XX*^]H@F:(UHI*<YJN?#I85KOPL(*0[OJYY8J+0:@FON5"\7-U9$%.P#R`
M=$3WCTY1AU<\X!ZF)/3.1:6A(%E/5.4XI[<TJCE4E*K#9'F";:Z!A:I*OIT+
M?H&,^_(Y_1AL5I6-B0*$DW/EB<QW2+3G,P.*]VI8S2=+P>Y*L3J*QRBYE2PN
M0`8YZC-FJ2]83]&+^WI,%LN5S0+&ZI`-?UB@>].6(AT5A2*HB(43383<XXS)
M@`BN!^6?CU)R_P"L0.W-_,C=MKMY?)RUL_"JG,];G>R_/T%^"?_:``@!`0,!
M/R$('9<&O:`I\*N$.3Q&BYC7RX+U!3=4.J,>JAY"#A%UV;F1Y`4MR6#!=6I!
M;@^O?GL>LN\#7S>J5^H2HNY>JP/0`_['S?BM7@5YB"H)CA:YRN8C2%W!>-D]
M`M<8H(HS#1]A)&!S.LT&R)R(]%71K6&&#SVE=@40[0%[ND=J"LF0=<DL=G6K
M'.I`UL7<VE!A`EQ-Q),9(H;B["ZCT3-&N10`06"P&`_`'G_O"#P[1*R7]KB2
M.%GOA":#AQ*,+V8S8VZZ6DLF?6L'H:1!(JFDA6<C2$8K[IC5E!=*2`^F=LA#
M?MD@O1"&!=]):0YVZ!!62`ZETA8T7JRM-&5947(OA2@%H?(H$]OS"KD5$((6
M"WD6RM`CKMO=<9QLWJ\Y`YD;+04"`20".XW&H,N=B[Y.L(%($WA)G]X,5=;+
M@10U"@:^L257`6M5N8V=AF-)E67J(LJ:2&;&*R!$Y*+96QE#!9\F;-!6NHB)
M!AW7!94H)M%H^$CQ>&S44I"(2FR@,2:D&2%T\@RX`2+'B1-)L"&@<68"2G0@
M`>`9%,AMHC]*CD.1W$,[BO63;6DQ?"D$\$@X'P(;[FV*!"P]\4.?-AB,X]`)
MA!1ZK6@1BM&#,&6@E6@+IB%Q$R412]\,)B-5Z&^PE)2A]Z0;P`FX(;!*M>H)
MDCG9&*RL>"7'C<!,`21#24PL^,`675+0P_G%8#)^3R6B48=`HTAN&27Q:&9:
MQ@TIT=Q!>RH6"S8$`O)U%8ENPHJTV&$26:B=3;A@W^T39H"N`)9+/#">$IMC
M)GO:F!"3*F>[_F2"J*R2(TNJ*9FH+U[]J>*$/4AN-2;9"1<M54PT+N72G5%`
M9/"3+Y4J[3FF[D^$91"JDNE;8\/=9-!8"XM3TA?)9=Q4N1D#KX),W<Y5XS/$
MD4<%"L?T,V2S"VCYIF-F2L"1P]0IIX<W"AZ=M13C<B4ZP,4>4S*5R"$;H$)M
M%*E;6!-Z*+S)$?"+XW?%B#=1PVH`1DX;9G:$-R]**%CUY%`,6`I.+87"[`0D
MZJ:Q3,$B\S9731$[(8"BJ%E0+-ZN3=ML<_)!L:PT5OVR'ARB\4&P;EN$,NG-
M)A5[5C-.:77S4M80T.60W`.(\QQ"_2%,V1I4TT&JY,.=)SS5I/`HH]'R@5I-
MF8EY,9$@3***WA\L62XP"T8N8123[BG0-[49(UKK0)DJ!8*,;#K)!PL3`@PV
MJQ7W)<7<E"P4YTG*WC(L(6H$E,%$&[0+/"Q)NT@(`2J8!=52P%/W17<PD8QT
M!2>#QRU()+"&\Z2<B9&%U42M1)/3>!I]"J0V,C!T'SQOHE:RN/ZU`$DT6]_T
M[OY1M._AXP8)J'1HTSW``!LC(I7!`_FQE$YQ&+LWGRT1);@@S1[4Y"KF^$@N
M`@7M\DWTU4=J)B%D_9P(5GDQ,+NE-@+<]Q`.8V)I/6<@&;2;+O630(GLB)4R
M`4F7A!A@0J9@S$4T-1XJPO[2V!HHAG2)0(%`:%`2J@0(!`VA%R1?S0\(\B9F
MC1]FG\K2-^_'VHQS^)__V@`(`0(#`3\ABO?Q1I6V8O'4R>U!R#Y(3P?#Y%`E
MQ6]MVQ[X^:O(C?Z_\YHM_P!K^R#"9/6U9DZ+;[*`Z&7?-6"UOZDI.%[-`!DO
M</U-"P?KK4N6^FU:K]O[J8';38ZZ?NF1"[#'MKU?P4!DHN9W>F3Y*]DW1Z5C
MF>+?JIU(,5D!7-6,<%/7C_U^BM5FKJ^!$%NN#W:O<$SE'6,4F/)XZU=EK1#'
M6]2<D<Q#]^"P)`.Z9\3CD'8W&@5@S6O;XP^4U="[5PZI,4.C(>4-#K-N2K)9
MK.7^]?!-NV%B:+K&J=#I^J,'`\2D;[8E7Z13'G$W+D)#*:4UL`>5T'2_@Q*8
M3T=&C&94XF^)T[K,T1&'-%+'S_#N_$T#C">M&_3P``):?=04[1_=Z(KBO(A8
M33#CM8']ZUEBF1?6E<&!IH&@.[5Y&3,XIVX\C[/YXLB09<)]-JB-6-RSSDC/
M[IM8W8C',<3/BQS\)]OKO6I0B`%V<'>AT'CM.O\`>]*9C4`>B_%^]*A[3`8<
M;EO:LF?O&CW*<:8S=&5AM..U$U!!TFWFLW?[:U#MR5K$C_/*B/'`W"-AQVH,
MCNV`_7@>B$0Q%SFE)9Z%28]A_*129I@6&,0=+4C*E[5-N"S-=?F07]5KR^<(
M]HH4Z#(EJN(&6"7J^9`2PU)O4_7^5=F6?+-N3&-:#$6*%B"V%JF"LI&&B:C6
M0I)9?I3*=3%<)0D)DYBU<12=(2H:G<:@R/.+73?V5Q0/+B84WC4V3'>IO>5!
M);[VBE$R(I6S*.YWVXTI3)$@J[FA'W1`T!]FI!82A#A+)_SP`HOH/.S^Z3,$
MJ[AYT3R1\G]_*A)._P")_]H`"`$#`P$_(9;47J/7Q\UAZ>286Q]GDSBO]C^9
MK+W_`.[F=CBFG6ZWM2CV!1772%`L,VGS1K-,B$IT9J3_`*"BQ9RY?S\$49,T
M;V[6L%<6HIM,2IK$,=*@A*T>DSUK4NP\&P<TY&.MJ3!0N*@9Q-9C'@*PVF/$
MJ7),5BM:Z-:%N]-*0Y?+\`5\D1@\-0;Z>SCEK47XNUK4/U5DC[I`6!;O6?IT
MIGA:4D=*F[9]/6/!6AEI<R/3UCPD+_2*:]2S.U18R3R`:L%!([S6@)PU)[6K
MVU:G<(JR+>'^^(2;(:3``)DKI?6?IT\!Q2_\H7NG3K2\<_R@XA8^Z6,TOQ1F
M=2O3VK%9AFE7RCS7)BRI#FH$R(_OEA8$<*DS?PQB8H`(H)DS232*(L^`!8PH
MZ&*:%U:TI)>@L"#S##)FK?T5QD>6(3Q-"F#-09-JE0RT@2XJ5&5,29M6B\!#
M.?`;2ZUNQ2NOG=]L_=26]\L+]R/9XI0.U,44`U@:"+4]>]7<X2*;%F<T#9V2
MAAFD1F6B)OBD*%YM1$\%.R9\\"XO\/Y1,/XG_]H`#`,!``(1`Q$``!"#@#@"
MX\``````:F.^R2```````#=D9/!3*"`(RT`2\&L"7/250=8`)'?M!VD1XET0
M``5,``("P&$[X``!@`!L(#_@VT```<`!73?+?80```````````````"`````
M````#__:``@!`0,!/Q"4@JO83DH9N-C52@1D%#,OH@=0?&;3$F9/;U!!Y$$;
M_%PAED#R*+^(QD^>X%"N0DD4(T*T!AHN.\%&KG36PW"0W_DB/PYJX$:'_837
M&9K,,G*(K"*2QOBO3"Z>ILT%KBH4E;"I@G)0YF"C:,DDD",R4L,'43L]Z*%%
M-DK&H\(+,NQ#7YD\TMA.M_%*30@0C<@)"@SCND2%TQ>LT"WUM,)4"&0+6G16
MG:*7L`I5A#``````0`%@#\!H\3@+-;A0-`T-+J`8S:4B\<H:]?&O,ZP@@(1S
M0RFJ,"S+79FZSK5R8%+!'24(:(9'3S1N$E#$P6ERAZ+#O`/P)8O%.'*=P.34
M&SRJ(-`MBX,+JP#@7X(,6-@2;A""!4%XJ>#J'?,EH2+*"F#6UJQ#-$M*Z-Z"
M#`D+,65.#LVJ3BFS$7B+T=@QL#`<(T^*2E$`4%E`(?&A#;U.JCQ`J!1/"'<"
M5!#A)H4_+FHF,F%#-TC!IS(H@Q"J9W5,0Q;=PRE@7]G1400\4`@(B(DB-D1L
MB5/[<Q1`@_`2HJA9</\`&&<AD"#X8=)9+LH>2@@FI`#5U29`TRJ`R9V"`$^V
M``$'XA/7WV7F%>E`=5#];#<LK($0HA$\,,2U"<!$9-?,36^0-Z=;<3."L5"3
M9%&+8A<%%KKJNTE!UC6X\<F&3=TS:YU5?"](B"5I.MJX>B3IM"*'*[/&(&0(
M$9O4?1JI?9!8Q0Q(B2=>U,FI-J!H,Z4YI*$@)8>0\40??8Q))@F-=2$P>HA=
M*QMF`P71%$2=,A)Q+T-0&PCN187QHT!9Q0^5I6NN@;4H#:8DK-%I5'!1"#D9
M=02G;)8#3*+4(22*H<()KX.RK<0\I?,JHE!829$6;7E/,0-B7Q!S8R$%BA6Q
M,CB9>@_KP1P.32H\-<@E$E@AQEI&5\=+PT(?1C/T,[I(ZXREU[LF23/($MI7
M=W'"DFQ>*IT,C4&#+,9&<!%>HT@I="5;ZX^G'%6#=4HD?@!(`)2"(\PGU&8'
MP5NABD0]!3*`C>#S@18H%T_GR\F<"T$\J'U/X#>-(:@+5"J"K6J<!84,GP4^
M:`:33^&,9``76""(=PS:VH743$&BTO049P"*&8"0VP!5P`"R):D_0@:;6!*6
MR68W[PD]Y0`*4S4UAEL"OW#RQA9L5K&S-K+Z%R9I2DC&AE[Q](D(*G)*XT<5
M\3K)9O227+T'?NI*,),^496`@ZPI`)$-3HC+&QO```AOI'\$4(PDF,'#=Y5^
MT($+@9F.Q*2E0@#!%54!86K99V6WU4*_!0DDNB^0Z),1AI,=QH5H01B3:/V!
M$)Q*B05R&K_IA20LK9R22*)9T/98(L`@+TG$9Y:!(!*N*<#_`/P)]A:C!&1I
M]<@=362<(G&!#H=(T^@8(E+!>*/+AA6F'L+$B7\XAFDH3-A73WY:$4^T%QC<
M$NLKRPCU(6I)+G(PF*1GAG0XY`L*7J*T+85(W]D6EH-PA(<3-5;,8DF1]1+K
M)$ZF<GZ>!T\9GO3@"CJLS`.L#)=3-,8:/<[+$+G:4\D8BK*TJU`ZHV"T&B.V
M?9M*&158R`*2UM2;Y*5]P&1#+125_8[+R%*E3T`.B!*D"L7,T@R^;2*9P)'0
MAYRD1(:>X;"0.K\I[#7UF9_\C\3_V@`(`0(#`3\0&/&[Z;>RT20>H'L!WF.R
MU`E\(^YD[^066_[!]>21(#5L4NHRRS'6T]Q5O7>3TP/4'8J$(57_`+&FHBCI
M.INI':C%X8`EM#!YN.A0<28@[+'YBD(7!(>_V5\13]A4Q`WR.!=U>ZOT"!^Z
M/4FE?@?=9#=Q/LN]TH,QZI-N,`UFS6*-6A<<;,:IR<'X+\!"$21.2M2$Y@-X
M]!9C`!&^KY&O1OUJ63O6Y^GS2;.?E%"^&-[WG!5ZYU7X(/BN`G`"NP&7TTN!
M++6.#5TR:L7J`]^3)R[;!8\&-X0I`=E`GB9XH)A29"(NH2@W0.:(+PLB"S"E
M`+-VL,#,\"]X*"S=VJ]!,AH&Z"8YI$8<T"%HG"(.D],QACP(LX'*?N#N8;E&
MLQW#Y;4A-O#<F(P3-LYI8C&&!VR1W)4;]W;$>_E!0N25I+["Y-&YPTQI`F.*
M&XVR<7TID3-1$AZ_TS3MP7BB]IA&@++>=:^3@%U5U7U;QA27EDW#F`%(0"2(
MJ'G(0G0"4D*,Q5B`DS!(ZI1N&U?$_JC=)#A,*W"1-FC+Q."<KP%UV*`D+@!1
MD]`?#:D1H6$<B9*20,Z.%QWD'J:4-!#$-)!L8(!LFAX*VT1U5-P&$*RMEVDB
MP-V:=0H=#;0OL>2_/K0=W^"\4<4AD+W#*N4.T4HN,.*Q.)=5\0T!^/="]9DA
MAW'O<*F<Y(2DZ`S`8@0=:(C#;A?TO4G!0R28\(,C')(EA-9%#IS4D<$-Y"BF
M!,IB"R*^M@A*%I2$6C%J^-_7@<>+TH-HP(F$/5M21`+AFQ<#;"^0J/8RDU(B
M=5#Q07W%J`:!B$_XT+<U$!<-!>:[4A63D`[E^\#7I.5%`[LR-"593"TYWJ,L
M8V"A[1YIXI6'P'M?M4X9]@9/A*SR[IE#\3V\IIW"&80`$@$84$(B&91R*!AU
M)AU\+"P#$$V@7+N=Z$PPQ`<X`'O1`R"`@@66(LNS:K&^H'X1*PLLRA((-EK6
MTJ)269@/N!1B%``2(R(HHCM4OT064,$LH*FZ8-V9G!,WZUF;D`)A(B.U-;*2
M!`00`L&Z^9R,DCT;-:G$?*EIKOL+'V]_*(`D3(DLF%B!]9H,T2MM#-2I.Z6G
M:UKWJ%8&5B8#+:F)D1!(8<-S##?>U*"2`QE;`!=5P%Z@)A)A1;&I'W1`0`%I
MNL!8U:M2^Q089@$DEM9B(G7'-?\`B5-.P##`Q\TQ("E8F#M1K(2;>=5:5ZW?
MJ@/TGL7^?*N%N:3C8R#C<1:@0L(>Y%/'""2<(&'%KI>]/R"9."2)J!H*9E0M
M`LZQ93%FF`!YKBDD/"+?(WJ3(8!4F9R@Q;'>D4!N\X!BVK%!F0'N12JE`N%"
MQL&,WB:"1$A:<3S5^H@N87"`N+*<CQ2]`XEP36%##25GN%O.#^;T^@?E.?8=
M8_$__]H`"`$#`P$_$-@<GW28D3B4)Z,R[2XIV%.2/(AF[\'WY`5`EH"$@<8+
MTN78JPMV,>^W[W"EEG'_`&G0A<W%VWY(3>EMJ-[#N<GL[M(7GEF?'_M7R[LP
MOM9H^;UD_M)?HYG1?L*1@=U^J"P^C'RM8P-S;WM]TC)N0NZ:J\11Y)#EI[FC
M@[_@@E082@Y'8SWT?AVIEF/4R=3[+=*L/$-SYJ!M"1-WF_ZJP@>'VRUS^:MC
MJN*"\2<\'VJ:=F#0];^#@E^`E?8OWJ)+G$&72<O!>A`X)R]*M)F@D2>DE0$<
M\2)/N>`%$BZ@</BR,"2;C"4H)<5-;V3E9G$35@X\*R]!A>U#EC!Y6B\ZFYL_
M7S0YS=$3R28=S]>`A8+<$P5``=J_4?W.*>I*]@V./%(FVR0`CY2[S>&:)>YB
MS8(R0,7':CGE1PLEZVCP0/$E[.B<C<IUB'KWHN+[0ZG0(2@B27&DAEX.#5[$
M]XIECJGN>Y(\^!15!_.LPP@Q'=>M[7M3/&%GR.O\P]C^Q3(PN;B^T`<>\T*L
M!8`#K')2O90]FAPRR]"W]:O\*(2)-V-=9232@UWO/;^@ZM-K>`BA23>$8OU+
ME2XG`1<+"%F<8G:B`E;F<\3S$3XH(5.9#%]%N9>QO5R2,R5@8R]N]:QV6\>D
M=J%W-R!3JMR1VH%M)F5RYG#?I-8;;W#A.S-&7IC3+E!@R7AAR9I`I0>L7^?-
M#X+W:?-N]3+8/Q'U6/`NR)_COY1DZJK8JYE(7O2H2H9)5AWAM//@Z(M23+#N
M7M4(3#RU#I[G^T`AQ[?JAA98D76]Z%@0=6FQRR$O".]9.Z8%#]UH>R+FSK,T
MJ,0A&XG,YH1$<$L$["P>9"M!D[5'`C_?^U;6(=V[]>WEB*8+%[QB8HLS)@O2
MI&^=^8[WVJ#56@OK1!F:DC))DZUEIA.=#*[%#*I19F]!T=P5OH9KD:01024D
MD.D_&:Y&B4D!)R8J(96VO2&%,><-P5TM1VM1^?*3Y,`8ZBR&;:ZU".4/M4J=
MTWTO/?XJ8Y`VXH=!&<81U33<F2C0$O49ABYW.^*L--V0#$8UZYI0"C:<D4QG
M(C[5!018M9<WV[5;WWWBM=A(TG(\-HC$4*BI-JM[C6(CSKS$/:_<?E8C$7_$
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
